THE FORUM FOR THE INDUSTRY EXECUTIVE

Volume 18 • Number 3
PUBLISHER Lisa Banket
EDITOR Taren Grom
CREATIVE DIRECTOR Marah Walsh

MANAGING EDITOR

Denise Myshko

SENIOR EDITOR

Robin Robinson

FEATURES EDITOR

Kim Ribbink

DESIGN ASSOCIATE

Ariel Medel

DIRECTOR OF SALES

Cathy Tracy

NATIONAL ACCOUNT MANAGER

Suzanne Besse

WEBCAST NETWORK PRODUCER

Daniel Limbach

CIRCULATION ASSISTANT

Kathy Deiuliis

Copyright 2018 by PharmaLinx LLC, Titusville, NJ Printed in the U.S.A. Volume Eighteen, Number Three

PharmaVOICE (ISSN: 1932961X) is published monthly except joint issues in July/Aug. and Nov/Dec., by PharmaLinx LLE, P.O. Box 327, Titusville, NJ 08560. Periodicals postage paid at Titusville, NJ 08560 and additional mailing offices.

Postmaster: Send address changes to PharmaVOICE, P.O. Box 292345, Kettering, OH 45429-0345.

PharmaVoice Coverage and Distribution:

Domestic subscriptions are available at \$190 for one year (10 issues). Foreign subscriptions: 10 issues US\$360. Contact PharmaVoice at P.O. Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your order to 609.730.0197.

Contributions: PharmaVOICE is not responsible for unsolicited contributions of any type. Unless otherwise agreed in writing, PharmaVoice retains all rights on material published in PharmaVoice for a period of six months after publication and reprint rights after that period expires. E-mail: tgrom@pharmavoice.com.

Change of address: Please allow six weeks for a change of address. Send your new address along with your subscription label to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345. Call us at 800.607.4410 or FAX your change to 937.890.0221. E-mail: mwalsh@pharmavoice.com.

IMPORTANT NOTICE: The post office will not forward copies of this magazine. PharmaVoice is not responsible for replacing undelivered copies due to lack of or late notification of address change.

Advertising in PharmaVOICE: To advertise in Pharma-VOICE please contact our Advertising Department at P.O. Box 327, Titusville, NJ 08560, or telephone us at 609-730.0196. E-mail: lbanket@pharmavoice.com.

Letters ...

ਗ

Send your letters to feedback@pharmavoice.com. Please include your name, title, company, and business phone number. Letters chosen for publication may be edited for length and clarity. All submissions become the property of PharmaLinx LLC.



recycled p

Printed on


Is the industry at a fork in the road?

Can an industry that has traditionally based its business model on researching, developing, and commercializing pills and other therapeutic interventions successfully pivot to adapt to a growing wave of consumer-centric wants and needs that address more than the diagnosis?

In this month's cover story, several industry experts discuss this timely topic, and Shideh Sedgh Bina, founding partner of Insigniam goes so far to state that a company must decide if its purpose is to provide health or to provide medications. She, like others, says this is a conversation that cannot be ignored for much longer.

Sedgh Bina believes if a company decides its mission is to provide health, it needs to move beyond the pill and if it doesn't it will no doubt face competition from other companies looking to move into the space.

That competition will no doubt come from the tech sector, and



Michael Fergusson, CEO of Ayogo, predicts that there also will be a whole wave of acquisitions of behavioral health companies. He also sees a shift in what pharma companies are asking for in terms of solutions and digital innovation, they are seeking turnkey solutions rather than undertaking the task of building or designing of the program or app themselves.

According to RockHealth, in the first half of 2017, \$3.5 billion was invested in almost 190 digital health companies, setting a record for the number of companies funded and the total amount invested in digital health

One of biggest areas that is ripe for beyond-the-pill disruption is that of chronic disease. With about half of adults suffering from one or more chronic diseases, which account for seven of 10 deaths and 86% of healthcare dollars, there is a real need for a conversation that moves the needle beyond pill dispensing. Compounding matters, experts say the average patient can take upward of 13 medications per day. According to Adele Gulfo, an industry veteran, the most difficult of the chronic disease to manage, and most expensive diseases include diabetes, COPD, and heart failure. These chronic diseases place a burden on individuals, their families, and the health system.

She is somewhat optimistic to see some companies starting to focus on identifying the right healthcare solutions, services, and technologies to complement their vast product portfolios and franchises. However, she says, as long as the healthcare system is out of alignment around incentives to support chronic care management, as well as to promote wellness and prevention in general, reimbursement for digital technology tools will struggle in a world of fee-for-service instead of fee-for-value or outcomes-based care.

This leaves the industry at a crossroads, and while the model may not change for some years yet, the pill industry just might become the health industry after all.



Their word...



DENISE MYSHKO Managing Editor



Having a diverse patient population in clinical trials is important since medicines affect

people differently based on age, sex. and race.

ROBIN ROBINSON Senior Editor



To provide value beyond the medicine, the industry is expanding its use of patient support

programs.

KIM RIBBINK

Features Editor



RNAi technologies offer potential to overcome the limitations of traditional drug

therapies to treat a range of diseases.

April 2018 SPECIAL ISSUE Patients

- Opinion Leaders
- ClinicalTrials
- Apps
- Health Literacy
- Advocacy Groups
- Business Strategies
- Chief Patient Officers
- Journeys
- Showcase:Global Markets

